Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second-quarter ...

Germany's Merck KGaA raised its full-year guidance for growth in underlying earnings, thanks to better prospects for its life-sciences and healthcare segments, but turned more cautious on sales.

On August 4, Tom Lee, co-founder and managing partner of Fundstrat Capital, and chairman of BitMine, joined CNBC Television ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

JCD Group has, in recent years, completed 440,000 sq. ft of new buildings in Blarney Business Park with occupiers including ...

It’s a bad time to try to predict future pharmaceutical prices.

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1100 ET – Bayer is expecting a historically high U.S. corn ...